Skip to main content
OpenTrials
Completed

NCT Number: NCT04424524

Streamlining the Efficiency of PrEP Implementation

This is a pilot facility-based direct-to-pharmacy PrEP refill delivery to streamline care pathway in Kenyan public health HIV facilities implementing PrEP. Data on up to 500 PrEP users will be evaluated to understand delivery efficiency and in-depth interview with users and delivery key informants will be conducted to identify barriers and facilitators of implementation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Partners in Health Research and Development

Thika, Kenya

About this study

A prospective, pilot implementation evaluation of patient-centered differentiated care service. The core components of the multifaceted implementation strategy include: 1) 3-monthly refills, 2) direct-to-pharmacy refill visits, 3) HIV self-testing (HIVST) while waiting for refills, 4) Rapid risk assessment for ongoing risk, adherence, side effect, and acute HIV symptoms. Clinics will implement either: 1) current PrEP patient flow without any change or 2) a pilot differentiated pharmacy-based follow up PrEP care pathway. Clinics will implement only one delivery model thus eliminating risk for confusion in the clinic about delivery models and permitting a full-scale test of the system, since the efficiency in PrEP delivery is in part at the system level, above and beyond the individual client encounter. For this pilot project designed to primarily test delivery efficiency, feasibility and acceptability of direct-to-pharmacy care pathway at systems level using existing public health infrastructure, pilot and control clinics will be of comparable size selected to reflect the implementation nature of the design.

The specific aims are:

Aim 1: To evaluate whether a differentiated care model improves the efficiency of PrEP delivery while resulting in equivalent or better: 1) patient waiting time, 2) early PrEP continuation, and 3) adherence.

Aim 2: Conduct mixed-methods study to understand patient and provider perception, experiences , feasibility and acceptability of a differentiated PrEP delivery model.

Aim 3: Assess the efficiency, cost and cost-effectiveness of a facility-based differentiated PrEP care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For HIV-negative participants:

  • Of legal age (≥18 years)
  • Able and willing to provide written informed consent for research component of the project (blood draw for adherence, brief surveys and in-depth qualitative interviews)
  • HIV uninfected based on negative HIV tests, per Kenya national guidelines
  • Currently or previously accessed PrEP at participating HIV clinic

For Key delivery informants:

  • Able willing and able to provide consent in order to participate in the survey and qualitative interviews.
  • Works at any of the clinics implementing PrEP delivery. Key informants may include HIV testing service nurses, counselors, clinicians, social workers, or clinic managers.

Exclusion criteria

  • Not meeting any of the inclusion criteria listed above.

Treatment and study plan

Direct-to-pharmacy oral PrEP refill visits

Other

Programmatic direct-to-pharmacy oral PrEP refill visits supported with client HIV self-testing

Primary outcomes

  1. Patient wait time

    Time frame: up to 6 months

    Total waiting time at the clinic and contact time with providers measured by time and motion studies

  2. PrEP continuation

    Time frame: up to 6 months

    Measured by return to clinic for PrEP refill

  3. PrEP adherence

    Time frame: up to 6 months

    Measured objectively through tenofovir levels in dried blood spots at random subset of PrEP visits

  4. Acceptability of direct-to-pharmacy PrEP care pathway

    Time frame: up to 6 months

    Assessed by the Acceptability of Intervention Psychometric Measure (AIM)

  5. Acceptability of user HIV self-testing for PrEP care pathway

    Time frame: up to 6 months

    Assessed by the Acceptability of Intervention Psychometric Measure (AIM)

  6. Feasibility of direct-to-pharmacy PrEP care pathway

    Time frame: up to 6 months

    Assessed by the Feasibility of Intervention Psychometric Measure (FIM)

Secondary outcomes

  1. Barriers to implementation of direct-to-pharmacy PrEP care pathway in Kenyan public health HIV clinics

    Time frame: up to 6 months

    Evaluated through in-depth and key informants qualitative interviews

  2. Facilitators to implementation of direct-to-pharmacy PrEP care pathway in Kenyan public health HIV clinics

    Time frame: up to 6 months

    Evaluated through in-depth and key informants qualitative interviews

  3. Fidelity of implementing of direct-to-pharmacy PrEP care pathway in Kenyan public health HIV clinics

    Time frame: up to 6 months

    Extent to which core components of the direct-to-pharmacy PrEP care pathway are implemented as intended will be evaluated through checklists and surveys with clinic managers

  4. Safety of HIV self-testing

    Time frame: up to 6 moths

    Accuracy of HIV self-testing measured by frequency false negative and positive tests.

  5. Reasons for PrEP discontinuation

    Time frame: up to 6 months

    Measured through in-depth qualitative interviews and surveys with persons who discontinue PrEP use

  6. Cost of implementing direct-to-pharmacy PrEP care pathway in Kenyan public health HIV clinics

    Time frame: up to 6 months

    Measured through micro-activity costing and time and motion studies

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Collaborators

  • National Institute of Mental Health (NIMH)

Registry information

Official study title

An Implementation Project to Improve the Efficiency of PrEP Delivery in Public Health HIV Care Clinics in Kenya

Acronym: Efficiency

Important dates

Study start
2020
Primary completion
2023
Study completion
2024
First posted
Jun 11, 2020
Registry last updated
Aug 13, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.